Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemoprevention.
We have generated transgenic mice which express the gene encoding Escherichia coli nitroreductase (NTR) specifically in the luminal epithelial cells of the mammary gland and the glial cells of the brain. The enzyme activates an antitumour drug CB 1954, to produce a cross-linking agent that kills all cells expressing the enzyme. We have shown that administration of the antitumour drug CB 1954 rapidly and selectively kills these cells. Original experiments demonstrated the ability to ablate the luminal cells in the mammary gland with no apparent bystander effect. Subsequently, astrocytes expressing nitroreductase under the targeting of the GFAP promoter were selectively ablated following administration of the prodrug CB 1954 produces a degeneration of granular neurones due to changes in glutamate levels. Recent experiments demonstrated inhibition of myc-dependent mammary tumours using the same enzyme (nitroreductase)-prodrug (CB 1954), combination. Owing to the ease of control of NTR-mediated cell ablation, we anticipate that this system will supersede herpes simplex virus type 1 thymidine kinase. There are widespread potential applications for this approach in the dissection of complex cellular interactions during development and in the adult organism. The present transgenic models also have important applications for the study in vivo of novel prodrugs that can be selected for variable degrees of bystander effects. Such studies will have particular significance for those groups advocating the use of NTR as an appropriate enzyme for gene-directed enzyme prodrug therapy by providing models of a wide range of human disease for mechanistic and therapeutic experimentation. The results clearly demonstrate that the model has potential to study chemoprevention and fundamental questions on cell-cell interactions in cell biology.
Gusterson
Barry A
BA
Department of Pathology, Western Infirmary, Glasgow G11 6NT, UK.
Cui
Wei
W
Clark
A John
AJ
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001253:Astrocytes / Q000473:pathology*; D001921:Brain / Q000473:pathology*; D002450:Cell Communication; D018890:Chemoprevention; D004195:Disease Models, Animal; D018390:Gene Targeting; D006801:Humans; D008321:Mammary Glands, Animal / Q000201:enzymology / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D009601:Nitroreductases / Q000235:genetics; D011355:Prodrugs / Q000008:administration & dosage
D000970:Antineoplastic Agents; D011355:Prodrugs; D009601:Nitroreductases